SMURF2 and cancer: The data (Figure 4e and Figure S2a,b) show that despite the heterogeneous expression of SMURF2 in different BRCA strains, SMURF2 has a higher cytoplasmic/nuclear ratio in cancer cells in comparison to the non-tumorigenic MCF10A cell model, supporting our findings obtained in clinical tissue samples.